A series of P1-P3 linked macrocyclic BACE-1 inhibitors containing a hydroxyethylamine (HEA) isostere scaffold has been synthesized. All inhibitors comprise a toluene or Nphenylmethanesulfonamide P2 moiety. Excellent BACE-1 potencies, both in enzymatic and cell-based assays, were observed in this series of target compounds, with the best candidates displaying cell-based IC 50 values in the low nanomolar range. As an attempt to improve potency, a phenyl substituent aiming at the S3 subpocket was introduced in the macrocyclic ring. X-ray analyses were performed on selected compounds, and enzymeinhibitor interactions are discussed.
. General structures of the macrocyclic target compounds (see Table 1 ).
azide group in compound 2 was achieved using 1,3-propanedithiol and TEA in methanol to provide the corresponding amine 3 in 73% yield. Target compound 17 was prepared as described in Scheme 3. Compounds 21-23
and 27-33 (Table 1) were synthesized using the same synthetic route and with similar yields (benzylamine was used instead of 3-isopropylbenzylamine in the final step for compounds 21 and 30, and 3-tert-butylbenzylamine was used for compound 22).
Compound 12a was prepared in 83% yield from compound 11 in a peptide coupling step using 3-butenylamine hydrochloride, EDC, HOBt, and TEA. The ester functionality in 12a was hydrolyzed using aqueous LiOH in H 2 O/dioxane and the corresponding carboxylic acid was coupled with compound 3 using HATU and DIPEA in DMF to afford compound 13 in 90% yield over two steps. The acetal in 13 was then hydrolyzed (AcOH/H 2 O, 60 °C), resulting in the diol 14 (quant.). The subsequent ring closing metathesis step was achieved utilizing Hoveyda-Grubbs catalyst 2nd generation in refluxing DCM to give the desired 15-membered macrocycle 15 in 98% yield. The cyclization resulted in exclusive formation of the trans isomer, as confirmed by 1 H-NMR analysis. Attempts to cyclisize compound 13 were unsuccessful, tentatively because of the more rigid structure found in 13. The primary hydroxyl group in 15 was selectively tosylated with p-TsCl, Bu 2 SnO, and TEA in dry DCM to generate compound 16 (64%).
Finally, the tosylate 16 was reacted with 3-isopropylbenzylamine in refluxing ethanol, furnishing target compound 17 in 37% yield. The amide nitrogen in 12a was methylated using NaH and MeI in DMF to give compound 12b in 100% yield. This building block was used to synthesize target compound 27, which proved to be a separable mixture of cis-27 (regio chemistry at the macrocyclic double bond position) and trace amounts of a related compound that tentatively could be identified by NMR analysis as the trans isomer. Noteworthy, the methylated amide functionality in 27 seems to have changed the preferred regio chemistry in the macrocycle from trans to cis.
The synthesis of compounds 19 and 20 is outlined in Scheme 4. Compound 18
was synthesized in the same manner as compound 15 with the exception that 4-pentenylamine hydrochloride 21 was used instead of 3-butenylamine hydrochloride in the peptide coupling step (see Scheme 3) . Hydrogenation of the double bond in compound 15
and 18 was achieved in the presence of Pd-C in methanol to give compounds 19 and 20 in 95% and 78% yield, respectively. To obtain the three saturated macrocyclic compounds 24-26, the same synthetic route was used as for compound 17 (see Scheme 3) with the exception that benzylamine was used instead of 3-isopropylbenzylamine in the final step for compound 24. with a 240-fold improvement compared to 21, whereas compound 22 showed a 120-fold increase in cellular activity.
Biological data and structure activity relationships
The 16-membered macrocycle 23 was synthesized to investigate the way ring-size of this series affects biological activity. This resulted in a 13-fold loss of activity in the enzymatic assay and a 30-fold loss in the cell-based assay compared to inhibitor 17. All attempts to synthesize the corresponding 14-membered macrocycle were unsuccessful.
The somewhat more flexible saturated macrocycles 24-26 were prepared in order to see if the double bond affected potency. Compound 24 lost almost all its activity in both assays, while compound 25 kept the enzymatic activity but had a 20-fold drop in the cell-based assay compared to 17. Interestingly, the 16-membered macrocycle 26 gained activities compared to its unsaturated analogue 23 and showed nearly similar potencies as inhibitor 17. This result may be explained by the fact that this 16-membered macrocycle's enhanced flexibility allowed it to mimic the conformation of its 15-membered unsaturated counterpart.
Compound 27 showed similar enzyme activity as 17, which possibly could indicate that substitution of the P2-P3 amide is non-critical for BACE-1 activity.
Furthermore, since inhibitor 27 was tested as the cis isomer and the rest of the unsaturated macrocyclic targets were identified as trans (see above), the configuration of this double bond tentatively seems not to be crucial for activity in this series of compounds.
A phenyl substituent was introduced in the macrocyclic ring in compounds 28 and 29 in an attempt to reach into the S3sp and further optimize potency. The (S)-isomer 28 displayed almost 30-fold less enzyme activity and 110-fold less cellular activity compared to 17. However, the (R)-isomer 29 yielded a small improvement of the enzymatic activity compared to inhibitor 17 and a 15-fold improvement of the cell activity.
Although some of the sulfonamide-based BACE-1 inhibitors displayed very high potencies all compounds exhibited poor cell-based Caco-2 permeability (around or less than 1x10 -6 cm/s). 22 Other BACE-1 inhibitors with a sulfonamide group in the P2 position have been shown to lack permeability due to for example P-gp efflux. 9 Replacement of the sulfonamide group with a less polar methyl substituent (compounds 30-33) led merely to decreased potencies and no permeability improvement could be observed.
Inhibition of cathepsin D for selected compounds at an inhibitor concentration of 10 M: 17 (23%), 22 (10%), 28 (46%), 31 (30%), and 33 (14%).
X-ray crystallography analysis
Compounds 28 and 33 were co-crystallized with BACE-1 (PDB ids: 4DPF and 4DPI, respectively). The general binding mode of the P1-P3 macrocyclic BACE-1 inhibitors was as anticipated for HEA-inhibitors ( Figure 2 ). [23] [24] [25] [26] The protonated amino and hydroxyl groups form hydrogen bonds with the catalytic aspartates Asp32 and Asp228, respectively. The carbonyl of Gly34 also forms a hydrogen bond with the ionized amine. Moreover, the P2´ isopropyl substituted benzyl has a snug fit to the S2´ 
Conclusion
In summary, a series of macrocyclic BACE-1 inhibitors containing a Even though we could achieve low nanomolar BACE-1 activity and good selectivity, the compounds synthesized suffered from inadequate permeability tentatively preventing them from reaching the CNS. Future work should be aimed at designing inhibitors with enhanced brain permeability, while retaining the reported potencies.
Experimental section

BACE-1 enzyme assay
The BACE-1 assay was performed as previously described. 
BACE-1 cell assay
The cell-based assay was performed as previously described. 
Caco-2 assay
The permeability measurements were performed as previously described. 
Cathepsin D assay
The cathepsin D enzyme assay was performed as previously described. 
Chromatography system B
Column: XBridge C8, 50x4.6 mm, 2.5 m; pump: Gilson gradient pump 322;
UV/VIS-detector: Gilson 152; MS detector: Thermo Finnigan Surveyor MSQ; Software:
Gilson Unipoint 4.0 and Xcalibur 1.3. Mobile phase A: 10 mM NH 4 OAc in water; mobile phase B: 10 mM NH 4 OAc in 90% acetonitrile; gradient: 35-100% B over 7 min at 1 mL/min followed by 100% of B for 3 min at 1 mL/min. Peaks were detected at 254 nm.
Synthesis
(S)-4-((S)-2-(Allyloxy)-1-azidoethyl)-2,2-dimethyl-1,3-dioxolane (2).
Compound 1 (129 mg, 0.69 mmol) was dissolved in toluene (2.5 mL 
(S)-2-(Allyloxy)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethanamine (3).
Compound 2 (126 mg, 0.55 mmol) was dissolved in MeOH (3 mL). TEA (386 L, 
(S)-1-Phenylbut-3-yn-1-ol ((S)-4).
Lithium acetylide ethylenediamine complex (2.24 g, 21.9 mmol) was added to dry 
(R)-1-Phenylbut-3-yn-1-ol ((R)-4).
Compound ( 
(R)-(1-Azidobut-3-yn-1-yl)benzene ((R)-5).
(S)-(1-Azidobut-3-yn-1-yl)benzene ((S)-5).
Compound (S)-5 (299 mg, 76%) was synthesized from (R)-4 in the same manner as (R)-5 and was collected as a colorless oil. 
(R)-1-Phenylbut-3-yn-1-amine ((R)-6).
1,3-Propanedithiol (3.5 mL, 34.8 mmol) was added to a solution of (R)- 
(S)-1-Phenylbut-3-yn-1-amine ((S)-6).
Compound (S)-6 (905 mg, 87%) was synthesized from (S)-5 in the same manner as compound (R)-6 and was collected as a colorless oil. 1 
(R)-Methyl 3-methyl-5-((1-phenylbut-3-yn-1-yl)carbamoyl)benzoate ((R)-7).
Compound (R)-6 (270 mg, 1.86 mmol) and 3-methoxycarbonyl-5-methylbenzoic acid (506 mg, 1.76 mmol) were dissolved in DMF (8 mL). DIPEA (0.92 mL, 5.3 mmol) and HCTU (1.09 g, 2.6 mmol) were added and the mixture was stirred at room temperature for 4 h. The solution was diluted with brine and H 2 O and extracted with EtOAc. The combined organic extracts were dried, filtered and co-evaporated with toluene. The residue was purified using flash column chromatography (toluene/EtOAc 
(R)-Methyl 3-(N-methylmethylsulfonamido)-5-((1-phenylbut-3-yn-1-yl)carbamoyl)benzoate ((R)-8).
Compound (R)-8 (649 mg, 89%) was synthesized from (R)-6 in the same manner as compound (R)-7, using compound 11 instead of 3-methoxycarbonyl-5-methylbenzoic acid, and was collected as a white powder. 1 
(S)-Methyl 3-(N-methylmethylsulfonamido)-5-((1-phenylbut-3-yn-1-yl)carbamoyl)benzoate ((S)-8).
Compound (S)-8 (381 mg, 89%) was synthesized from (S)-6 in the same manner 
(R)-Methyl 3-methyl-5-((1-phenylbut-3-en-1-yl)carbamoyl)benzoate ((R)-9).
Compound (R)-7 (27 mg, 0.08 mmol) was dissolved in MeOH (7 mL 
(S)-Methyl 3-methyl-5-((1-phenylbut-3-en-1-yl)carbamoyl)benzoate ((S)-9).
Compound (S)-9 (213 mg, 99%) was synthesized from (S)-7 in the same manner as (R)-9 and was collected as a white powder. 1 
(R)-Methyl 3-(N-methylmethylsulfonamido)-5-((1-phenylbut-3-en-1-yl)carbamoyl)benzoate ((R)-10).
Compound (R)-10 (326 mg, 84%) was synthesized from (R)-8 in the same manner as (R)-9 and was collected as a white solid. 1 
(S)-Methyl 3-(N-methylmethylsulfonamido)-5-((1-phenylbut-3-en-1-yl)carbamoyl)benzoate ((S)-10).
Compound (S)-10 (1.5 g, 92%) was synthesized from (S)-8 in the same manner as (R)-9 and was collected as a white solid. 1 
Methyl 3-(but-3-en-1-ylcarbamoyl)-5-(N-methylmethylsulfonamido)benzoate (12a).
Compound 11 (414 mg, 1.44 mmol) was dissolved in DMF (5 mL). 
Methyl 3-(but-3-en-1-yl(methyl)carbamoyl)-5-(N-methylmethylsulfonamido)benzoate (12b).
Compound 12a (429 mg, 1.3 mmol) was dissolved in DMF (6 mL). NaH (60%) 
N
-((S)-2-Allyloxy-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-ethyl)-N 3 -but-
3-enyl-5-(methanesulfonyl-methyl-amino)-isophthalamide (13).
Compound 12a (429 mg, 1.26 mmol) was dissolved in H 2 O (8 mL) and dioxane (16 mL). Aqueous LiOH (1.5mL, 40 mg/ml, 60 mg, 2.5 mmol) was added and the reaction mixture was stirred at room temperature for 1 h and 10 min. The solution was co-evaporated with toluene and the crude material was re-dissolved in DMF (12 mL). 
N-[(E)-(S)-4-((S)-1,2-Dihydroxy-ethyl)-2,13-dioxo-6-oxa-3,12-diaza-
bicyclo[12.3.1]-octadeca-1(18),8,14,16-tetraen-16-yl]-N-methylmethanesulfonamide (15).
Compound 14 (119 mg, 0.25 mmol) was dissolved in dry DCM (200 mL) and the solution was degassed with N 2 . Hoveyda-Grubbs catalyst 2nd generation (37 mg, 0.06 mmol) was added and the reaction mixture was refluxed overnight under N 2 atmosphere.
The solution was subsequently concentrated and the crude material was purified using flash column chromatography (MeOH/EtOAc 1:12 
Toluene-4-sulfonic acid (S)-2-hydroxy-2-[(E)-(S)-
N-{(E)-(S)-4-[(R)-1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-2,13-
dioxo-6-oxa-3,12-diaza-bicyclo[12.3.1]octadeca-1(18),8,14,16-tetraen-16-yl}-
N-methyl-methanesulfonamide (17).
Compound 16 (80 mg, 0.14 mmol) and 3-isopropylbenzylamine (57 mg, 0.38 mmol) were dissolved in EtOH (99.5%, 5 mL) and the reaction mixture was refluxed for 24 hours. The mixture was concentrated and the crude product was purified using flash column chromatography (MeOH/EtOAc 1:9 + 1% TEA). 
N-[(E)-(S)-4-((S
)
N-[(S)-4-((S)-1,2-Dihydroxy-ethyl)-2,14-dioxo-6-oxa-3,13-diaza-
N-[(E)-(S)-4-((R)-2-Benzylamino-1-hydroxy-ethyl)-2,13-dioxo-6-oxa-
3,12-diaza-bicyclo[12.3.1]octadeca-1(17),8,14(18),15-tetraen-16-yl]-N-methylmethanesulfonamide (21).
Compound 21 was synthesized according to the synthetic route for 17, using benzylamine in the final step, and was collected as a colorless oil (42% for the final step).
[] D +54.3 (c 0.1, MeOH Compound 27 was synthesized from 12b according to the synthetic route for 17
N-{(E)-(S)-4-[(R)-2-(3-tert-
N-{(E)-(S)-4-[(R)-1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-2,14-
N-[(S)-4-((R
N-{(S)-4-[(R)-1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-2,14-
and was collected as a colorless oil (5% for the final step Compound 30 was synthesized from 3-methoxycarbonyl-5-methylbenzoic acid according to the synthetic route for 17, using benzylamine in the final step, and was collected as a colorless oil (48% for the final step 
N-{(E)-(4S,11S)-4-[(R)-1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-
N-{(E)-(4S,11R)-4-[(R)-1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-
(E)-(S)-4-((R
(E)-(S)-4-[(R)-1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl]-16-
(E)-(4S,11S)-4-[(R)-1-Hydroxy-2-(3-isopropyl-benzylamino)-ethyl
